三重信心支撑科创板科创成长层“开门红”

Core Insights - The successful debut of three unprofitable companies on the Sci-Tech Innovation Board reflects strong market confidence driven by their technological capabilities, the board's supportive framework, and alignment with national innovation strategies [1][4]. Group 1: Company Insights - Xi'an Yiswei is the first 12-inch silicon wafer manufacturer in mainland China and ranks sixth globally, holding the highest number of authorized patents in its field domestically, addressing critical supply chain gaps during a key period for semiconductor domestic substitution [2]. - Wuhan Heyuan Bio and Guangzhou Bibete focus on innovative biopharmaceuticals, with Heyuan Bio overcoming technical bottlenecks in recombinant human albumin drug development and Bibete targeting unmet clinical needs in cancer treatment with globally pioneering drug research [2]. Group 2: Industry Insights - The Sci-Tech Innovation Board's clear positioning and differentiated institutional advantages provide a precise listing pathway for high-tech companies that are unprofitable but possess significant technological barriers, showcasing the board's support for "hard tech" enterprises throughout their lifecycle [3]. - The board's optimized disclosure requirements for growth-stage companies enhance transparency, allowing investors to make informed decisions about the value of these enterprises [3]. - The alignment of these companies with the national strategy of "innovation-driven development" highlights their role in the critical sectors of semiconductor and biomedicine, which are essential for ensuring supply chain security and promoting high-quality economic growth [4].